FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897601505> ?p ?o ?g. }

• W2897601505 endingPage "3832" @default.
• W2897601505 startingPage "3817" @default.
• W2897601505 abstract "The use of therapeutic monoclonal antibodies (mAbs) has revolutionized cancer treatment. The conjugation of mAbs to nanoparticles has been broadly exploited to improve the targeting efficiency of drug nanocarriers taking advantage of high binding efficacy and target selectivity of antibodies for specific cell receptors. However, the therapeutic implications of nanoconjugation have been poorly considered. In this study, half-chain fragments of the anti-EGFR mAb cetuximab were conjugated to colloidal nanoparticles originating stable nanoconjugates that were investigated as surrogates of therapeutic mAbs in triple negative breast cancer (TNBC). Three TNBC cell lines were selected according to EGFR expression, which regulates activation of MAPK/ERK and PI3K/Akt pathways, and to distinctive molecular profiling including KRAS, PTEN, and BRCA1 mutations normally associated with diverse sensitivity to treatment with cetuximab. The molecular mechanisms of action of nanoconjugated half-chain mAb, including cell targeting, interference with downstream signaling pathways, proliferation, cell cycle, and apoptosis, along with triggering of ADCC response, were investigated in detail in sensitive and resistant TNBC cells. We found that half-chain mAb nanoconjugation was able to enhance the therapeutic efficacy and improve the target selectivity against sensitive, but unexpectedly also resistant, TNBC cells. Viability assays and signaling transduction modulation suggested a role of BRCA1 mutation in TNBC resistance to cetuximab alone, whereas its effect could be circumvented using half-chain cetuximab nanoconjugates, suggesting that nanoconjugation not only improved the antibody activity but also exerted different mechanisms of action. Our results provide robust evidence of the potential of half-chain antibody nanoconjugates in the treatment of TNBC, which could offer a new paradigm for therapeutic antibody administration, potentially allowing improved curative efficiency and reduced minimal effective dosages in both sensitive and resistant tumors." @default.
• W2897601505 created "2018-10-26" @default.
• W2897601505 creator A5003506844 @default.
• W2897601505 creator A5011206324 @default.
• W2897601505 creator A5013212240 @default.
• W2897601505 creator A5028842822 @default.
• W2897601505 creator A5034709962 @default.
• W2897601505 creator A5046028029 @default.
• W2897601505 creator A5049196878 @default.
• W2897601505 creator A5054387609 @default.
• W2897601505 creator A5067982846 @default.
• W2897601505 creator A5075376801 @default.
• W2897601505 creator A5077280546 @default.
• W2897601505 creator A5078271751 @default.
• W2897601505 creator A5088698720 @default.
• W2897601505 creator A5091107534 @default.
• W2897601505 date "2018-10-10" @default.
• W2897601505 modified "2023-09-23" @default.
• W2897601505 title "Half-Chain Cetuximab Nanoconjugates Allow Multitarget Therapy of Triple Negative Breast Cancer" @default.
• W2897601505 cites W1555009525 @default.
• W2897601505 cites W1580407891 @default.
• W2897601505 cites W1758612015 @default.
• W2897601505 cites W1965205681 @default.
• W2897601505 cites W1966634965 @default.
• W2897601505 cites W1968885065 @default.
• W2897601505 cites W1974245465 @default.
• W2897601505 cites W1978068596 @default.
• W2897601505 cites W1978710044 @default.
• W2897601505 cites W1979147887 @default.
• W2897601505 cites W1988975697 @default.
• W2897601505 cites W2006168411 @default.
• W2897601505 cites W2012629036 @default.
• W2897601505 cites W2019986565 @default.
• W2897601505 cites W2031998778 @default.
• W2897601505 cites W2032427485 @default.
• W2897601505 cites W2040070170 @default.
• W2897601505 cites W2040540434 @default.
• W2897601505 cites W2042012206 @default.
• W2897601505 cites W2042884540 @default.
• W2897601505 cites W2043911313 @default.
• W2897601505 cites W2044151404 @default.
• W2897601505 cites W2045216597 @default.
• W2897601505 cites W2050584550 @default.
• W2897601505 cites W2057680108 @default.
• W2897601505 cites W2057980589 @default.
• W2897601505 cites W2068125497 @default.
• W2897601505 cites W2083375435 @default.
• W2897601505 cites W2094449657 @default.
• W2897601505 cites W2094540897 @default.
• W2897601505 cites W2095201384 @default.
• W2897601505 cites W2096027508 @default.
• W2897601505 cites W2111693820 @default.
• W2897601505 cites W2112845420 @default.
• W2897601505 cites W2116787167 @default.
• W2897601505 cites W2125163614 @default.
• W2897601505 cites W2125589729 @default.
• W2897601505 cites W2125616358 @default.
• W2897601505 cites W2127457668 @default.
• W2897601505 cites W2139513897 @default.
• W2897601505 cites W2143336748 @default.
• W2897601505 cites W2144169031 @default.
• W2897601505 cites W2144535642 @default.
• W2897601505 cites W2155082500 @default.
• W2897601505 cites W2168479321 @default.
• W2897601505 cites W2344600572 @default.
• W2897601505 cites W2402636472 @default.
• W2897601505 cites W2409420104 @default.
• W2897601505 cites W2474112260 @default.
• W2897601505 cites W2520018761 @default.
• W2897601505 cites W2526593384 @default.
• W2897601505 cites W2563743887 @default.
• W2897601505 cites W2564108037 @default.
• W2897601505 cites W2564610778 @default.
• W2897601505 cites W2568695943 @default.
• W2897601505 cites W2605191520 @default.
• W2897601505 cites W2748128788 @default.
• W2897601505 cites W2765386661 @default.
• W2897601505 cites W2767769854 @default.
• W2897601505 cites W2770583446 @default.
• W2897601505 cites W2774294088 @default.
• W2897601505 cites W2788206402 @default.
• W2897601505 cites W2793468148 @default.
• W2897601505 cites W2805686838 @default.
• W2897601505 cites W2915163461 @default.
• W2897601505 cites W4211075026 @default.
• W2897601505 doi "https://doi.org/10.1021/acs.bioconjchem.8b00667" @default.
• W2897601505 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30350574" @default.
• W2897601505 hasPublicationYear "2018" @default.
• W2897601505 type Work @default.
• W2897601505 sameAs 2897601505 @default.
• W2897601505 citedByCount "14" @default.
• W2897601505 countsByYear W28976015052019 @default.
• W2897601505 countsByYear W28976015052020 @default.
• W2897601505 countsByYear W28976015052021 @default.
• W2897601505 countsByYear W28976015052022 @default.
• W2897601505 countsByYear W28976015052023 @default.
• W2897601505 crossrefType "journal-article" @default.
• W2897601505 hasAuthorship W2897601505A5003506844 @default.

• next